NCT04611932Unknown1 期
A Randomized, Open-label, Single Dose, 3-period Partial Replicated Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- AUCt of CKD-330, D090, CKD-333
研究概览
简要总结
This study is a randomized, open-label, single dose, 3-period partial replicated crossover study to evaluate the pharmacokinetic profiles and safety of CKD-333 low dose in healthy volunteers under fasting conditions.
详细描述
To healthy subjects of fifty-one (51), following treatments are administered dosing in each period and wash-out period is a minimum of 14 days.
Reference drug: 1) Cantabell Tab. 8/5mg 2) Lipitor Tab. 10mg / Test drug: CKD-333 8/5/10mg Tab.
Pharmacokinetic blood samples are collected up to 72hrs. The pharmacokinetic characteristics and safety are assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 54 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults over the age of 19 years and under the age of 55 years at the time of screening
- •Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) < 30.5kg/m2 and men's total body weight ≥ 55 kg, women's total body weight ≥ 45 kg
- •* BMI = Weight(kg)/ Height(m)2
- •Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years
- •Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, urinalysis, viral/bacterial, etc.) and vital signs, ECG etc. performed at screening
- •Individuals who signed an informed consent form approved by the IRB of Chonbuk National University Hospital and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content and characteristics of the investigational product
- •Individuals who agreed proper contraception during the study and did consent to not donation of sperm 1 month after the last dose of study drug infusion
- •Individuals with the ability and willingness to participate the entire study period
排除标准
- •Individuals with a medical evidence or a history (excluding a dental history of periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune diseases.
- •Individuals with a medical history of gastrointestinal disease (e.g., gullet disease such as esophageal achalasia and esophagostenosis and Crohn's disease) or operations (excluding simple appendectomy, herniotomy or tooth extraction) that may affect drug absorption
- •Individuals with the following laboratory test results at screening:
- •ALT or AST > 2x the upper limit of the normal range
- •CK > 3x the upper limit of the normal range
- •History of regular alcohol consumption exceeding 210 g/week within the 6 months prior to screening (1 drink (250 mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12 g)
- •Individuals who smoked more than 20 cigarettes per day within 6 months prior to screening
- •Individuals who had been administered investigational product(s) from other clinical study or bioequivalence study within the 6 months prior to the first dose of this study
- •Following vital signs results at screening
- •Sitting systolic blood pressure ≥ 140 mmHg or < 90 mmHg and/or sitting diastolic blood pressure ≥90 mmHg or <60 mmHg
- •Individuals with a medical history of significant alcohol or drug abuse within one year prior to the screening
- •Individuals who had taken any drug(s) known as a strong inducer(s) or inhibitor(s) of drug-metabolizing enzymes within 30 days prior to the first dose of investigational product(s)
- •Individuals who had taken prescription or nonprescription drugs within the 10 days prior to the first dose of investigational product(s)
- •Individuals who donated whole blood within the 2 months, or blood components within 1 month prior to the first dose of the investigational product(s)
- •Individuals with severe acute/chronic medical or psychiatric condition that may increase the risk associated with study participation or investigational product(s) administration, or may interfere with the interpretation of study results
- •Individuals with hypersensitivity to investigational products or the investigational products ingredients or dihydropyridine drugs
- •Patient with hyperkalemia
- •Patients with hepatopathy
- •Patients with hereditary angioedema, ACE inhibitors or angiotensin Ⅱ receptor antagonists who have a history of angioedema
- •Primary hyperaldosteronism
- •Patients with aortic valve stenosis, mitral (valve) stenosis, hypertrophic obstructive cardiomyopathy
- •Patients with ischemic heart disease, ischemic cardiovascular disease, cerebrovascular disease
- •Patients with Intravascular volume depletion
- •Patients with nephropathy (eGFR<60 ml/min/1.73 m2)
- •Patients with renal artery stenosis
- •Patients with muscle disease
- •Patients with Hypothyroidism
- •Women who are pregnant or may be pregnant
- •Patients with a history of muscle toxicity when using statins or fibrates
- •Patients who are taking glecaprevir/pibrentasvir
- •Patients with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption etc.
- •Individuals who were deemed to be inappropriate to participate in the study by the investigator
研究组 & 干预措施
Test-Reference-Reference
Experimental
干预措施: CKD-333 Tab. (Drug)
Reference-Reference-Test
Experimental
干预措施: CKD-330 Tab. and D090 Tab. (Drug)
Reference-Reference-Test
Experimental
干预措施: CKD-333 Tab. (Drug)
Reference-Test-Reference
Experimental
干预措施: CKD-330 Tab. and D090 Tab. (Drug)
Reference-Test-Reference
Experimental
干预措施: CKD-333 Tab. (Drug)
Test-Reference-Reference
Experimental
干预措施: CKD-330 Tab. and D090 Tab. (Drug)
结局指标
主要结局
AUCt of CKD-330, D090, CKD-333
时间窗: Pre-dose (0 hour), post-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
Area under the CKD-330/D090/CKD-333 concentration in blood-time curve from zero to final
Cmax of CKD-330, D090, CKD-333
时间窗: Pre-dose (0 hour), post-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, 72 hours
The maximum CKD-330/D090/CKD-333 concentration in blood sampling time t
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy VolunteersCardiovascular DiseaseNCT04478097Chong Kun Dang Pharmaceutical51
已完成
1 期
A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted StateProstatic HyperplasiaNCT00537654GlaxoSmithKline81
已完成
1 期
Clinical Study to Compare the Pharmacokinetics and Safety of D113 With CKD-349 in Healthy VolunteersChronic Renal FailureNCT04952506Chong Kun Dang Pharmaceutical25
已完成
1 期
Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.HypertensionNCT00557128GlaxoSmithKline24
已完成
1 期
Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted ConditionsPharmacokineticsNCT02561741Mallinckrodt30